If you suffered losses exceeding $50,000 in Applied Therapeutics January 3, 2024 and December 2, 2024 and would like to ...

New York, New York-- (Newsfile Corp. - February 7, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Applied Therapeutics, Inc. (NASDAQ: ...

Weight loss drug users are spending up to $690 less per year on groceries. Find out which foods they’re ditching the most.

February 4, 2025) - Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Applied Therapeutics, Inc. (NASDAQ: APLT) securities between January 3, 2024 and December 2, 2024, both ...

The outcome of the review has come as a major disappointment for patients and their families, with the Galactosemia Foundation calling the outcome "devastating" and urging the FDA to "reconsider ...

In support of its New Drug Application (NDA) for govorestat for the treatment of galactosemia, Applied Therapeutics relied on data from its phase 3 ACTION-Galactosemia Kids trial in children ages ...

Wilson Encourages Investors Who Suffered Losses In Applied Therapeutics To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Applied ...

including Classic Galactosemia, Sorbitol Dehydrogenase (SORD) Deficiency and PMM2-congenital disorder glycosylation (CDG).

Advances in genetic testing, enable the identification of genetic causes even before symptoms appear, allowing for timely ...

Galactosemia, Phenylketonuria, Gaucher Disease, Pompe Disease, Fabry Disease, MPS II (Hunter Syndrome), MPS IV (Morquio Syndrome), and Osteogenesis Imperfecta preventive oral health services to ...